Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why These Five Stocks Are in the Spotlight Today

Despite there being just a couple more days to go until November 8, the market is surprisingly calm as all three major indexes are moderately in the green.

In this article, we will examine the reasons why PTC Therapeutics, Inc. (NASDAQ:PTCT), Centurylink Inc (NYSE:CTL), Michaels Companies Inc (NASDAQ:MIK), Tesla Motors Inc (NASDAQ:TSLA), and SolarCity Corp (NASDAQ:SCTY) are each in the spotlight and we will assess the hedge fund sentiment towards these stocks.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

Tesla Motors Inc (NASDAQ:TSLA), Car, Model S, Sign, Showroom, Brand, Logo, automotive, sales

Hadrian /

PTC Therapeutics, Inc. (NASDAQ:PTCT) has bounced back by 17% after yesterday’s over 30% plunge. PTCT shares fell yesterday due to the company including the following in its earnings report:

“While we have provided information in response to the CHMP’s requests and expect to continue to engage in further interactions, recent dialogue has introduced a higher degree of uncertainty as to the outcome.”

PTC could really use the advisory committee’s approval if Translarna is to remain commercially available in the EU. A thumbs down from the CHMP would not be helpful for Translarna’s availability. With the rally today, it seems that some traders think that the company could still potentially satisfy the CHMP and keep Translarna on the market in the EU. Of the 749 funds we track, 13 funds owned $22.28 million worth of PTC Therapeutics, Inc. (NASDAQ:PTCT)’s stock, which accounted for 9.20% of the float on June 30, versus 12 funds and $40.31 million, respectively, on March 31.

Follow Ptc Therapeutics Inc. (NASDAQ:PTCT)
Trade (NASDAQ:PTCT) Now!

Centurylink Inc (NYSE:CTL) shares have inched up 1% after the company announced that it had reached an agreement to sell datacenters and colocation business to a consortium led by Medina Capital and BC Partners. In exchange, CenturyLink will receive $2.15 billion in cash subject to various adjustments, and a minority stake to be valued at $150 million in the consortium’s newly formed global secure infrastructure company. Management plans to use the proceeds to fund its purchase of Level 3 Communications. A total of 28 funds from our database were long Centurylink Inc (NYSE:CTL) as of the most recent 13F reporting period, down by three funds from the previous quarter.

Follow Centurylink Inc (NYSE:CTL)
Trade (NYSE:CTL) Now!

On the next page, we examine Michaels Companies, Tesla Motors, and SolarCity Corp.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.